K-RAS mutations indicating primary resistance to crizotinib in ALK-rearranged adenocarcinomas of the lung: Report of two cases and review of the literature
Introduction
Anaplastic Lymphoma Kinase (ALK) gene rearrangement was identified in about 5% of non-small-cell lung cancer (NSCLC) patients, often characterized by adenocarcinoma (ADC) histotype, younger age and no or light-smoking history. The vast majority of these cases are wild-type for Epidermal Growth Factor Receptor (EGFR) and Kirsten rat sarcoma viral oncogene homolog (K-RAS) genes analysis [1], [2]. ALK-positive adenocarcinomas are highly responsive to the triple ALK, c-MET, ROS1 inhibitor crizotinb in about 65% of cases [3], [4]. The median clinical response is of about 10 months, but relapse inevitably occurs and secondary resistance is generally due to occurrence of ALK mutations, ALK gene amplification and activation of escape signalling pathways [5]. No consisting data are reported concerning the mechanisms leading to primary resistance in 30–40% of ALK-positive patients unresponsive to crizotinib [6], [7]. Novel and more potent ALK-inhibitors, namely ceritinib, alectinib and brigatinib, have been developed to overcome primary or acquired resistance to crizotinib [6]. The concomitant occurrence of K-RAS mutations and ALK rearrangement have been recently described in a subset of adenocarcinomas, generally leading to primary resistance to crizotinib [7], [8], [9], [10], [11], [12], [13]. We report here two additional patients, a 49-year-old smoker male and a 59-year-old non-smoking woman, with advanced pulmonary adenocarcinoma harboring concomitant K-RAS mutations (G13D; Q61H) and ALK rearrangement experiencing rapid disease progression on chemotherapy and crizotinib. No ALK gene mutations were detected. The role of the “undruggable” KRAS mutations as negative predictive marker [14] in ALK rearranged adenocarcinoma is discussed.
Section snippets
Case 1
In September 2014, a 49-year-old man, heavy smoker presented to our Institution with seizures. CT and RM-brain imaging showed 2 frontal and a cerebellar metastatic lesions. Chest-CT revealed a solid mass of the right upper lobe and enlarged mediastinal lymph nodes. A bronchial biopsy was performed and a diagnosis of primary pulmonary adenocarcinoma was made (stage IV according to the 7th AJCC/UICC tumor staging system) (Fig. 1). At immunohistochemistry (IHC), tumor cells were positive with
Discussion
About 65% of ALK-rearranged lung adenocarcinomas respond to crizotinib and the occurrence of ALK mutations seems to represent the most important mechanism of secondary resistance [3], [4], [5], [6]. However, few data are available concerning primary resistance and the presence of concurrent gene alterations in ALK-rearranged tumors has been poorly investigated [5], [6], [7].
We report here 2 cases of ALK-rearranged (both positive by FISH assay, while 1 positive and 1 negative by IHC)
Conflict of interest
The authors declare no conflict of interest.
References (24)
- et al.
Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
Lancet Oncol.
(2011) - et al.
Parallel FISH and immunohistochemistry studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances
J. Thorac. Oncol.
(2014) - et al.
Dragging ras back in the ring
Cancer Cell
(2014) - et al.
The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer
Cancer Genet.
(2013) - et al.
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK
J. Clin. Oncol.
(2009) - et al.
ALK rearrangements are mutually exclusive with mutations in EGFR or KRAS: an analysis of 1683 patients with non-small cell lung cancer
Clin. Cancer Res.
(2013) - et al.
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer
N. Engl. J. Med.
(2010) - et al.
Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies
Clin. Cancer Res.
(2014) - et al.
Treatment of ALK-rearranged non-small cell lung cancer: recent progress and future directions
Drugs
(2015) - et al.
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer
Clin. Cancer Res.
(2012)
Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report
BMC Res. Notes
Combined point mutation in KRAS or EGFR genes and EML4-ALK translocation in lung cancer patients
Future Oncol.
Cited by (39)
Molecular and therapeutic bases of cancer
2021, Oncological Functional Nutrition: Phytochemicals and Medicinal PlantsEfficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
2020, Lung CancerCitation Excerpt :Information on co-occurring genetic alterations is not available in these patients, but it is likely some patients with a smoking history have additional mutations, rendering the ALK inhibitors less beneficial. There is evidence that concomitant oncogenic mutations, related to tobacco use, may cause primary resistance or be negatively prognostic in patients receiving ALK inhibitors [40–43]. There appeared to be a greater degree of benefit with second-generation ALK inhibitors compared to crizotinib in patients with intracranial disease, although this difference did not reach significance.
RASSF1A: A promising target for the diagnosis and treatment of cancer
2020, Clinica Chimica ActaCitation Excerpt :There is a close association between RAS mutations and drug resistance in standard therapies [142,143]. Some case reports have suggested that KRAS mutations may lead to resistance to anaplastic lymphoma kinase inhibitors, such as crizotinib, in NSCLC patients [144]. In addition, many lung cancer patients may be resistant to reactive oxygen species 1 inhibitors and eventually relapse due to the activation of RAS [145].
RAS-mediated oncogenic signaling pathways in human malignancies
2019, Seminars in Cancer Biology